The obesity-treatment pipeline is becoming increasingly crowded with next-generation incretin drugs. One of the newer names moving rapidly through late-stage development is ribupatide, also known as KAI-9531. Ribupatide is an investigational once-weekly dual GIP and GLP-1 receptor agonist peptide being developed for obesity and overweight. What makes it particularly interesting is that the global Phase...Read More

The next generation of obesity medicines is increasingly focused not just on which receptors are targeted, but also on how treatments are delivered and maintained over time. VK2735 is one of the more interesting examples. It is an investigational dual GIP and GLP-1 receptor agonist being developed by Viking Therapeutics in both: once-weekly injectable form...Read More

Survodutide is one of the most advanced next-generation peptide drugs being studied for obesity and metabolic disease. Unlike traditional GLP-1 receptor agonists, survodutide targets two hormone pathways at once: the GLP-1 receptor the glucagon receptor That dual mechanism is designed to combine reduced food intake with increased metabolic activity. And unlike many experimental compounds that...Read More

The next generation of obesity medicines is moving beyond GLP-1 alone. One of the most interesting new candidates is eloralintide, an investigational once-weekly selective amylin receptor agonist being developed by Eli Lilly. Eloralintide is being studied both on its own and in combination with tirzepatide. That combination, known as EloraTZP, has already produced striking Phase...Read More

GLP-1 medicines have dominated obesity research for several years. But another hormone pathway is now becoming increasingly important: amylin. One of the most advanced compounds targeting this pathway is petrelintide, a long-acting amylin analogue being developed as a once-weekly treatment for obesity and overweight. Unlike GLP-1 receptor agonists, petrelintide is designed around a different biological...Read More

Most modern obesity and metabolic treatments focus heavily on reducing appetite and food intake. SANA, known as MVD1 during clinical development, is being investigated from a different direction. Rather than primarily suppressing appetite, this experimental small molecule is designed to increase energy expenditure through creatine-dependent thermogenesis. That makes SANA particularly interesting because it targets the...Read More

Most modern metabolic treatments focus heavily on reducing energy intake. ATX-304 is being investigated from a different angle. Instead of primarily targeting appetite, this experimental molecule is designed to influence cellular energy regulation, AMPK signalling and mitochondrial activity. That makes ATX-304 particularly interesting because it represents a different approach to metabolic research — one focused...Read More

Klotho has become one of the most discussed proteins in modern ageing and longevity research. It is sometimes described online as the “longevity protein” or even an “anti-ageing protein”. Those descriptions are catchy, but the real science is more interesting. Klotho is a naturally occurring protein involved in several important biological systems, including mineral metabolism,...Read More

FLGR242 has become one of the more talked-about experimental compounds in online muscle and longevity communities during 2026. It is commonly described as an engineered follistatin-derived protein designed to influence the myostatin pathway. That immediately makes it interesting from a research perspective. But FLGR242 also demonstrates something important about emerging compounds: scientific plausibility and actual...Read More

Interest in myostatin inhibition has grown rapidly because of the protein’s important role in regulating skeletal muscle growth. One of the newer research compounds attracting attention is MID-35, an experimental peptide being investigated for its ability to interfere with myostatin signalling. Unlike many compounds discussed online before meaningful research exists, MID-35 now has published preclinical...Read More